KR20140045903A - C형 간염 바이러스 억제제 - Google Patents
C형 간염 바이러스 억제제 Download PDFInfo
- Publication number
- KR20140045903A KR20140045903A KR1020137005316A KR20137005316A KR20140045903A KR 20140045903 A KR20140045903 A KR 20140045903A KR 1020137005316 A KR1020137005316 A KR 1020137005316A KR 20137005316 A KR20137005316 A KR 20137005316A KR 20140045903 A KR20140045903 A KR 20140045903A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- cap
- hcv
- methyl
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *N(CCC1)C1c1nc(C=IC=C2)c2[n]1 Chemical compound *N(CCC1)C1c1nc(C=IC=C2)c2[n]1 0.000 description 15
- KIBWZPHNDYFRFZ-UHFFFAOYSA-N C=Cc1cccnc1C(O)=O Chemical compound C=Cc1cccnc1C(O)=O KIBWZPHNDYFRFZ-UHFFFAOYSA-N 0.000 description 1
- HSNVSTHCNLNFRA-HNNXBMFYSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c([nH]c1c2)nc1ccc2C#C)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c([nH]c1c2)nc1ccc2C#C)=O HSNVSTHCNLNFRA-HNNXBMFYSA-N 0.000 description 1
- NJAZZJLGUNFMJG-WVQMWBIHSA-N CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2C#CC2C=C3NC([C@H](CCC4)N4C(OC(C)(C)C)=O)=NC3=CC2)[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2C#CC2C=C3NC([C@H](CCC4)N4C(OC(C)(C)C)=O)=NC3=CC2)[nH]1)=O NJAZZJLGUNFMJG-WVQMWBIHSA-N 0.000 description 1
- SHWXQAFHIHEYHL-GAGCMDECSA-N CC(C)(C)OC(N(CCC1C2)[C@@]12c1nc2cc(C#C)ccc2[nH]1)=O Chemical compound CC(C)(C)OC(N(CCC1C2)[C@@]12c1nc2cc(C#C)ccc2[nH]1)=O SHWXQAFHIHEYHL-GAGCMDECSA-N 0.000 description 1
- SYYUDQILXQFRAM-VIFPVBQESA-N CC(C)(C)OC(N1C=C(C)C[C@H]1C(OC)=O)=O Chemical compound CC(C)(C)OC(N1C=C(C)C[C@H]1C(OC)=O)=O SYYUDQILXQFRAM-VIFPVBQESA-N 0.000 description 1
- QCXSPVCVRZKCKS-CYBMUJFWSA-N CC(C)(C)OC([C@@H](Cc1ccccc1)NC(N(C)C)=O)=O Chemical compound CC(C)(C)OC([C@@H](Cc1ccccc1)NC(N(C)C)=O)=O QCXSPVCVRZKCKS-CYBMUJFWSA-N 0.000 description 1
- OAJYMDVCDGTWKR-UHFFFAOYSA-N CC(C1)c(c(Cl)ncc2)c2C=C1O Chemical compound CC(C1)c(c(Cl)ncc2)c2C=C1O OAJYMDVCDGTWKR-UHFFFAOYSA-N 0.000 description 1
- ZWVBAHITHMYEMS-SECBINFHSA-N CCNC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound CCNC(N[C@@H](C(O)=O)c1ccccc1)=O ZWVBAHITHMYEMS-SECBINFHSA-N 0.000 description 1
- BFZJLIVIZYCQDL-GFCCVEGCSA-N CCN[C@@H](C(OC(C)(C)C)=O)c1ccccc1 Chemical compound CCN[C@@H](C(OC(C)(C)C)=O)c1ccccc1 BFZJLIVIZYCQDL-GFCCVEGCSA-N 0.000 description 1
- RVBBBKNEWQFTQF-UHFFFAOYSA-N CCc([s]1)c(C(O)=O)nc1Cl Chemical compound CCc([s]1)c(C(O)=O)nc1Cl RVBBBKNEWQFTQF-UHFFFAOYSA-N 0.000 description 1
- INNRHBUYGJHSGL-UHFFFAOYSA-N CCc([s]1)c(C(OC)=O)nc1Cl Chemical compound CCc([s]1)c(C(OC)=O)nc1Cl INNRHBUYGJHSGL-UHFFFAOYSA-N 0.000 description 1
- NLPIZOSHELQGNL-SECBINFHSA-N CN(C)C(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound CN(C)C(N[C@@H](C(O)=O)c1ccccc1)=O NLPIZOSHELQGNL-SECBINFHSA-N 0.000 description 1
- SKCUMFJFAWFXDL-UHFFFAOYSA-N CN(C)C1(Cc2ccccc2C1)C(O)=O Chemical compound CN(C)C1(Cc2ccccc2C1)C(O)=O SKCUMFJFAWFXDL-UHFFFAOYSA-N 0.000 description 1
- CNLYTGPWBFKYPG-UHFFFAOYSA-N COc(cc1)cc2c1C(C#N)=NCC=C2 Chemical compound COc(cc1)cc2c1C(C#N)=NCC=C2 CNLYTGPWBFKYPG-UHFFFAOYSA-N 0.000 description 1
- VUQQDZRSKKRERE-UHFFFAOYSA-N COc1c(ccnc2C(O)=O)c2ccc1 Chemical compound COc1c(ccnc2C(O)=O)c2ccc1 VUQQDZRSKKRERE-UHFFFAOYSA-N 0.000 description 1
- HKWKVZRIFSAVLQ-UHFFFAOYSA-N COc1ccc2c(C(O)=O)nccc2c1 Chemical compound COc1ccc2c(C(O)=O)nccc2c1 HKWKVZRIFSAVLQ-UHFFFAOYSA-N 0.000 description 1
- VGOWSNRVKZXKNM-UHFFFAOYSA-N COc1cccc2c1ccnc2C#N Chemical compound COc1cccc2c1ccnc2C#N VGOWSNRVKZXKNM-UHFFFAOYSA-N 0.000 description 1
- REUMWVARHUGSQF-CQWWLZBFSA-N C[C@@H](C1)CN[C@@H]1c1nc(ccc2c3ccc(C#Cc(cc4)cc5c4[nH]c([C@H]4NC[C@@H](C)CC4)n5)c2)c3[nH]1 Chemical compound C[C@@H](C1)CN[C@@H]1c1nc(ccc2c3ccc(C#Cc(cc4)cc5c4[nH]c([C@H]4NC[C@@H](C)CC4)n5)c2)c3[nH]1 REUMWVARHUGSQF-CQWWLZBFSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N N[C@@H](C(O)=O)c1ccccc1 Chemical compound N[C@@H](C(O)=O)c1ccccc1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- YXKXUEHOOFXREU-LBPRGKRZSA-N OC(C[C@H](CCC1)N1C(Cc1ccccc1)=O)O Chemical compound OC(C[C@H](CCC1)N1C(Cc1ccccc1)=O)O YXKXUEHOOFXREU-LBPRGKRZSA-N 0.000 description 1
- QEEBXPXPYKOARL-UHFFFAOYSA-N OC(c1ncc[n]1Cc1ccccc1)=O Chemical compound OC(c1ncc[n]1Cc1ccccc1)=O QEEBXPXPYKOARL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/044356 WO2012018325A1 (en) | 2010-08-04 | 2010-08-04 | Hepatitis c virus inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140045903A true KR20140045903A (ko) | 2014-04-17 |
Family
ID=43640063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137005316A Abandoned KR20140045903A (ko) | 2010-08-04 | 2010-08-04 | C형 간염 바이러스 억제제 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2601188B1 (enExample) |
| JP (1) | JP5596861B2 (enExample) |
| KR (1) | KR20140045903A (enExample) |
| CN (1) | CN103153986B (enExample) |
| AU (1) | AU2010358561B2 (enExample) |
| BR (1) | BR112013002729A2 (enExample) |
| CA (1) | CA2807305A1 (enExample) |
| EA (1) | EA022127B1 (enExample) |
| IL (1) | IL224298A (enExample) |
| MX (1) | MX337936B (enExample) |
| SG (1) | SG187183A1 (enExample) |
| WO (1) | WO2012018325A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673954B2 (en) * | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| EP2616461A4 (en) | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2709455A4 (en) | 2011-05-18 | 2014-11-05 | Enanta Pharm Inc | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| IN2014MN01547A (enExample) | 2012-02-10 | 2015-05-08 | Lupin Ltd | |
| CA2869908C (en) | 2012-04-25 | 2018-02-20 | Theravance Biopharma R&D Ip, Llc | Hepatitis c virus inhibitors |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN110621652A (zh) | 2017-05-17 | 2019-12-27 | 株式会社德山 | 二氨基苯化合物的制造方法 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2020004043A1 (ja) | 2018-06-28 | 2020-01-02 | 株式会社トクヤマ | α－アジドアニリン誘導体又はα，α'－ジアジド誘導体の製造方法 |
| ES2967878T3 (es) | 2019-03-15 | 2024-05-06 | Medimmune Ltd | Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| AU2003266530A1 (en) * | 2002-09-20 | 2004-04-08 | Kirin Beer Kabushiki Kaisha | HEPATITIS C VIRUS INHIBITOR COMPRISING Alpha-GLYCOSYLCERAMIDE AS THE ACTIVE INGREDIENT |
| GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
| US8303944B2 (en) * | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2774927A1 (en) * | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
-
2010
- 2010-08-04 MX MX2013001237A patent/MX337936B/es active IP Right Grant
- 2010-08-04 EP EP10740116.8A patent/EP2601188B1/en not_active Not-in-force
- 2010-08-04 BR BR112013002729A patent/BR112013002729A2/pt not_active IP Right Cessation
- 2010-08-04 AU AU2010358561A patent/AU2010358561B2/en not_active Ceased
- 2010-08-04 CA CA2807305A patent/CA2807305A1/en not_active Abandoned
- 2010-08-04 SG SG2013005558A patent/SG187183A1/en unknown
- 2010-08-04 JP JP2013523129A patent/JP5596861B2/ja not_active Expired - Fee Related
- 2010-08-04 CN CN201080069468.6A patent/CN103153986B/zh not_active Expired - Fee Related
- 2010-08-04 KR KR1020137005316A patent/KR20140045903A/ko not_active Abandoned
- 2010-08-04 WO PCT/US2010/044356 patent/WO2012018325A1/en not_active Ceased
- 2010-08-04 EA EA201370017A patent/EA022127B1/ru not_active IP Right Cessation
-
2013
- 2013-01-17 IL IL224298A patent/IL224298A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2807305A1 (en) | 2012-02-09 |
| EP2601188B1 (en) | 2017-10-18 |
| WO2012018325A1 (en) | 2012-02-09 |
| JP2013532725A (ja) | 2013-08-19 |
| MX337936B (es) | 2016-03-29 |
| MX2013001237A (es) | 2013-05-28 |
| JP5596861B2 (ja) | 2014-09-24 |
| EP2601188A1 (en) | 2013-06-12 |
| SG187183A1 (en) | 2013-02-28 |
| BR112013002729A2 (pt) | 2016-05-31 |
| IL224298A (en) | 2015-08-31 |
| EA201370017A1 (ru) | 2013-05-30 |
| AU2010358561B2 (en) | 2016-06-02 |
| CN103153986B (zh) | 2014-11-05 |
| EA022127B1 (ru) | 2015-11-30 |
| AU2010358561A1 (en) | 2013-03-21 |
| CN103153986A (zh) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5612612B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5596861B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5558556B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| KR101614964B1 (ko) | Ｃ형 간염 바이러스 억제제로서 사용하기 위한 형태적으로 제한된 바이페닐 유도체 | |
| JP5599792B2 (ja) | Ｃ型肝炎ウイルス阻害剤としてのｂｉ−１ｈ−ベンズアミダゾール | |
| JP5847284B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5611959B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| US8394968B2 (en) | Hepatitis C virus inhibitors | |
| JP5632910B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5612661B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5455933B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| KR20120034603A (ko) | Ｃ형 간염 바이러스 억제제 | |
| KR20120107991A (ko) | Ｃ형 간염 바이러스 억제제 | |
| KR20130036173A (ko) | Ｃ형 간염 바이러스 억제제 | |
| HK1163067B (en) | Hepatitis c virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130228 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20150716 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160621 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20161010 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |